Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... you may want to get screened and treated for ... According to a first-of-its-kind study in the October ... of the American Society of Anesthesiologists (ASA), patients with ... prior to surgery are less likely to develop serious ... "OSA is a common disorder that affects millions and ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry ... He is a 13-year veteran in the school, commercial and ... A-Z Bus Sales of Colton, California. While with A-Z Mr. ... top line revenues, profit and market penetration by double digits. ... to all-electric or plug-in hybrid vehicle conversions. They have ...
(Date:9/23/2014)... Carbon nanotubes serve as bridges that allow electrical ... patches invented at Rice University and Texas Children,s ... Jacot and chemical engineer and chemist Matteo Pasquali ... nanotubes. The patches are made of a sponge-like ... body,s extracellular matrix. , The nanotubes overcome a ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
Breaking Medicine News(10 mins):Health News:New research suggests sleep apnea screening before surgery 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2
... 2010 -- The American College of Cardiology and ... Interventions has been accepted for coverage by Thomson ... the Journal Citation Reports. The Journal will receive ... "The Editorial Board and the American College of Cardiology ...
... According to a ... programs, such as Medicare and Medicaid, have prompted hospitals to shift costs to automobile insurance ... hospital bills prior to payment. , ... Malvern, PA (Vocus) April 23, 2010 -- According to a new study from ...
... ... lipoplasty will be discussed by leading experts at the Annual Meeting of the American ... Convention Center April 23-27, 2010. “Point/Counterpoint – Laser Lipoplasty – Hype or Useful ... and Jeffrey M. Kenkel, MD. , ...
... at risk for facial deformities, poor grades, dentists say ... the mouth instead of the nose can lead to ... mouth breathers, most often children with allergies, have problems ... size, weight, sleep and even school performance, a recent ...
... INDIANAPOLIS Structural and functional congenital cardiovascular abnormalities present ... defects encountered in live births. Nearly half a million ... ranging in severity from relatively simple issues, such as ... severe malformations, including complete absence of one or more ...
... ... will be pleased with the final result, there is a small chance ... The realities of revision in rhinoplasty will be discussed by leading experts ... Aesthetic Plastic Surgery (ASAPS), being held at the Gaylord National Hotel and ...
Cached Medicine News:Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 2Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 4Health News:Laser Lipoplasty: Cutting Through the Hype 2Health News:Laser Lipoplasty: Cutting Through the Hype 3Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 2Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 3Health News:New strategies to improve treatment and avert heart failure in children 2Health News:New strategies to improve treatment and avert heart failure in children 3Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 2Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: